Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Operating Leases (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Operating Leases for 7 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 46.11% to $27.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, up 46.11% year-over-year, with the annual reading at $27.6 million for FY2025, 46.11% up from the prior year.
  • Operating Leases hit $27.6 million in Q4 2025 for IDEAYA Biosciences, up from $26.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $27.6 million in Q4 2025 to a low of $611000.0 in Q2 2023.
  • Historically, Operating Leases has averaged $9.2 million across 5 years, with a median of $3.5 million in 2021.
  • Biggest five-year swings in Operating Leases: plummeted 76.24% in 2023 and later surged 1980.68% in 2025.
  • Year by year, Operating Leases stood at $3.5 million in 2021, then tumbled by 53.73% to $1.6 million in 2022, then crashed by 30.17% to $1.1 million in 2023, then surged by 1577.6% to $18.9 million in 2024, then surged by 46.11% to $27.6 million in 2025.
  • Business Quant data shows Operating Leases for IDYA at $27.6 million in Q4 2025, $26.9 million in Q3 2025, and $26.3 million in Q2 2025.